Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
this statement may yet be determined ...!
6 years later and aprox. +/- $130-Mil. in Accumulated Deficits...
and here's TOMDF SH's trustworthy, capable, competent, efficient, knowledgeable, and highly skilled, C-suite, highly self-proclaimed Stanford University undergrad "Financial Engineer" CEO had to say:
expecting further share reductions...
by the new prime acquisition - which has audited financials
followed by a new CUSIP announcement
just to clear out any bogus 'certificate' riff-raff that may linger...
BAF MONI...!
nobody wants to hear from Redsputter or JoeyForkitBolo
let alone Redsputters other fake alias theWordman
or JoeyForkitBolo’s other fake alias Warp or Warpcore
you and your ilk are a disgrace for pumping GC’s shams & atrocities
AMBS & TOMDF were PnD’s using the same toxic death spiral convertible financing that you were warned about
this CEO is a failed hack, a fake, a manipulator, and an opportunist - and should never be allowed touch the public’s $ again
there’s nothing else to get here - it’s all been said before:
risks are going to be what's exposed now if TOMDF goes BK - most prolly starting with a massive Class Action spear
MOO shills touts & dolts
in case you didn't get the news the 1st time around Pal...
https://investor.todosmedical.com/news-events/press-releases/detail/254/todos-medical-announces-insolvency-proceedings-in-israel
here's what MONI does have...
as opposed to that other sham now in Insolvency Proceedings
1. crystal clean SS
2. no debt on books
3. miniscule dilution over last 4 years
4. current Pink filing
5. timely security filings
6. small OH, GnA & OE's
7. reduced millions of shares w/no cost to SH’s
8. low consistent float moves on thin air
9. BitGift asset on books
10. BitGift trademark enforce
11. unencumbered by “dead weight” liabilities on books
12. huge untapped value in current Holdings Corp structuring
13. in final negotiations to acquire target as a wholly owned sub thru non-dilutive measures
14. new acquisition target is generating strong revenue’s
15. new acquisition target has “audited” financials
16. very real possibility of further share reductions
mo mo mo MONI...!
you can't approve something that does not require FDA testing &/or approval
uh hmm sounds just like sputtering Mr. Redspudder
again more false narratives being pumped on the ole TOMDF rag
yeah increasing and still printing $0.0002 pps
pathetic I tell ya
there's no way in hell anybody is going to get there $$$ back in this scam
and here's why Sporto:
https://investor.todosmedical.com/news-events/press-releases/detail/254/todos-medical-announces-insolvency-proceedings-in-israel
but hey, keep pumpin this shite - GC loves ya for it...!
why wait till BK - let's crack the Bubbley now - shall we Mr Redsputter...?
MOO played much?
the REAL problem is - the $$$'s gone sporto
https://finance.yahoo.com/news/todos-medical-announces-insolvency-proceedings-222800017.html#:~:text=In%20December%202023%2C%20a%20trustee,the%20Company%20going%20through%20liquidation.
SMH - what's not to get here touting buckeroo...?
oh that look on Shelly Crafts face says it all...!
MOO played
you only have this CEO hack to thank for your $$$ pain
you should have listened brah...!
Todos Medical Anti-Covid Pill my arse - pumping shill - are ye now....!!!
IMHO, that smirk says it all...!
if they can't raise $$$ in 3 more days - TOMDF is BK
and TOMDF SH's will be left at the bottom of the proceeding results - if there are any
the $$$ is prolly all gone - you're looking in the TOMDF rear view mirror
no audited financials and Pink non-reporting ain't good pal
SMH - sad but true...
MOO you been played
the problem is - TOLLO-Up Buttercup doesn't work Honey...!
the internet is flooded with bad reviews on Tollovid - just lookie here:
even the illustrious twice failed Financial Engineer CEO hack said it didn't work:
WWW flooded with piss poor reviews I tell you:
printing $0.0002
and that bid is prolly a fake, its a fugazi...
just like TOMDF and the twice failed Stanford "Financial Engineer" CEO hack
that bids prolly only there to entice the noob investor - it'll get pulled
post if you disbelieve this Redsputter character
SMH - credibility's shot pal
MOO shill & tout
just what do these lame BNO Feed Weekly US COVID updates have to do with Tollovid...?
or even Tollovir for that matter...?
which by the way has now been permanently shelved - no Greece or Israeli EUA as Gerald promised:
lookie here - Tollovid is not approved for shite - straight from the honest, truthful, and transparent CEO's mouth:
how can you plan for future LH Covid Tollo trials when you have no $$$ - or was this another bold faced lie:
there's countless GC TOMDF posts, PR's, tweets, etc. that are worthless and complete utter BS, like this one below:
time to button down those cheap dress shirt collars Gerry...!
SMH - can't make this stuff up Gerry...!
things are going to get rough around here Gerry
that Stanford University :Financial Engineering" Dept. will want their Diploma back
MOO furious
no real surprises that Gerald Commissiong twice failed untrustworthy and flunky CEO …
allowed TOMDF to lapse into OTC non-reporting status
and TOMDF’s accounting ledger no longer required formal CPA or Esq. audit oversight
ghee - makes one wonder - what the hell did they do with all that money…?
also got to wonder at what stage the forensics will be called in …?
one hell of a Christmas present to lay on Mrs. Commissiong and the kids - eh Mr Redsputter…?
worse yet, this is Gerald Commissiongs 2nd sham in a row of an SEC publicly traded security
the Fed’s not going to take kindly to any suspect activity that’ll become a focal point in discovery
SMH - a class action suit is all but guaranteed considering the way the stench is starting to smell
MOO greed utter incompetance & stoopidity
Todos Medical Announces Insolvency Proceedings in Israel
Press Release | 12/22/2023
https://www.wallstreet-online.de/nachricht/17658569-todos-medical-announces-insolvency-proceedings-israel
WOWZA - Tollovid is now "burnt offerings" - simultaneously TOMDF's "books are cooked"
TOMDF will soon be BK, as it teeters on the proverbial edge of unreconcilable insolvency
also with the twice failed Stanford "Financial Engineer" CEO hack Gerald Commissiong being the quintessential "link" between TOMDF and AMBS...
it stands to reason that TOMDF going BK will have a significant adverse impact on AMBS
not to believe so would only enforce ones own folly and inevitable downfall
would you trust this man with your family's hard earned honest money...?
MOO sad
its not about the Jr Pharma's ...!
do you have any idea how many AMBS & TOMDF SH's lost they're shirts because of this SHAM, and this twice failed CEO flunky hack...?
law suits are going to start flying fast & furious pal
starting with a massive Class Action law suit, followed by quite possibly civil and criminal suits as well...
just you watch - Gerald Commissiong will be hung-out-to-dry by the Todos Medical corp. hierarchy - and rightfully so...!
I hope it was well worth the $$$ to Gerald - a lot of good people got financially devastated of a result of his decade-long wreckless CEO stewardship of not 1, but 2 public securities
pumping an Anti-Covid Pill on public TV when one didn't exist - protected by forward looking statements was heinous...
but Gerald did it anyway - just for TODOS to be able to sell shares (equity distribution) into the media hype - time & time again:
there were so many other Tweets & PR's that were simply bogus, and Gerald knew it - and he knew it was wrong:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173466082
there's also a decade's worth of consistent, relentless and non-stop pumping going on by the TOMDF Boiler Room Pumpers, that are sure tobe be looked into as well
which caused for massive SH losses - there will be no place to run or hide for those responsible for these losses - they know who they are...!
I hope, trust & pray the judicial system permanently "bars" Gearld Commissiong from ever being able to touch another public security
or from having access to those public security moneys from their shareholders ever again...!
also how many times did SH's complain about terminating Gerald Commissiong - and to bring in a highly seasoned, competent, and trustworthy CEO...?
these things and a myriad of others will be looked into into by the judicial system - unfortunately it comes a little too late for the SH's who will end up with pennies on the dollar, or with anything at all...!
SMH - sad but true...
MOO (My Opinion Only) shills & touts
Les unfortunately once you are a TOMDF Boiler Room Pumping shill, tout, dolt, or tool, you will continue pumping what is now an INSOLVENT[\b] destitute and on the verge of BK non-SEC reporting SHAM until only an oil stain of it remaining on the carpet floor…!
call the SEC pal
I want to see Redsputters "real name" on their letter head...
you stoopid TOMDF touting fool...!
MOO u r forked
Todos Medical Announces Insolvency Proceedings in Israel
Press Release | 12/22/2023
https://www.wallstreet-online.de/nachricht/17658569-todos-medical-announces-insolvency-proceedings-israel
WOWZA - Giddy-Up Buttercup - Tollovid is now "burnt offerings" and your TOMDF horses along with your Todos CBD Gummie Bear vending machines are history pal
to put it mildly to ya, 'TOMDF's books are cooked' Mr Redsputter...
the sinking ship's cockroaches are now running for their lives - and I recommend you and your ilk do the very same brah - pack you 'glad rags' and vámonos for a good long while - subpoenas may well follow this news - if you get my drift - burner phones, fake IP's and fake email addy's ain't goin help you - wink wink...!
your reputation - along with that of JoeForkeyBolo, theWordman, Mauibound, Warpcore, GreeseMonkey, Gman111, NaturalTreasures, BMS, etc etc etc as well as the infamous faith-filled twice-failed scam-artist Stanford University undergrad "Financial Engineer" wannabe CEO hack Gerald Commissiong CEO are all permanently F'd...!
the shite's going to hit the fan - culpability will spread like a kitchen fire - but unfortunately, there won't be any place to run or hide - they've been a lot of good folks on these threads that lost all, they're $$$ listening to you and your ilk - I trying to warn you and the public about this scam, but the Back Office Promo Boys just had to keep pumpin this shite in spite of all the warning signs - to be frank, it must suck to being you pal...!
but hey, here's to you Mr Redsputter - the TOMDF gig is up and there will be hell to pay - I promise you and all the other TOMDF shills & touts exactly that:
don't want to say I told you so - but to you and TOMDF Boiler Room Pumper Boys can now read what I've been warning you guys about for years:
you know nothing about my losses with AMBS and how they came about
I lost $$$ on AMBS, but not to the pps, but to an agreement that was breached by GC
you're a FOOL that has to justify a continual TOMDF pps atrocity & Astoria Queens financial mafia toxic death spiral sham
that has so painfully morphed for all AMBS and TOMDF SH's - from there to here
all because you back this sham artist making $760k/yr, plus perks, retirement, auto, speaking fees, travel, etc etc etc
WHY is the only question you would do that Redsputter...?
and here's my answer to it - which is patently obvious:
I've said my peace - no need to defend myself you the likes of you - or the other TOMDF shill, touts and dolts...!
nuff said - you and them are a pathetic POS's brah
MOO tool
hey 'reputation shot' sputtering Mr Redsputter - whats happenin brah...?
sure ain't TOMDF that you been pumpin with the Boi's - now has it...?
you still hiding behind your Mickey Mouse keyboard pumping false narratives...?
yeah that's me - and proud of it - unfortunately you can't claim the same and be a 'stand-up man' now - can you...?
you'll remain a lil pumper Boi in hiding forever, scared of your own pathetic shadow
pretty amazing to think poorly of someone - just because of their email exchange - like that's what a man is really judged on
versus you and the TOMDF Back Office Promo Boi's using fake alises, fake emails, fake IP's, burner phones, and Gawd only knows what else:
the thread is on to you and your ilk sporto - your day of reckoning is upon you
also go ahead and show me where I've presented myself as a stock analyst anywhere else other than that mistaken Precision IR report - go ahead and pull them up pal
you know why you can't...? because they don't exist - only in between those 2 ears of yours that you call a head
but you'll continue dragging the dead mouse "fake analyst" mantra home like a cat dragging home its dead mouse prey:
creating false narratives like you do across the boards sowing seeds of untruths and false rumors
but that's just the sputtering Mr. Redsputter doing what he and the Boiler Room Boi's do...!
you've been outed more than me pal - my names is honorable and its out there - I stand behind everything I say and do
but you - you remain in hiding and continue your moronic attacks on me and my family by sending pizza to my home
and discrediting my daughter in public view - wow what a brave and honorable man you are - eh Redsie - does it make you feel good about yourself...?
that's just the type person you, JoeyForketBollo, and your alter ego alias "theWordman" are as humans - you guys are nothing more that shills, touts and dolts
you'll do anything to distract from the catastrophic AMBS VERB & TOMDF pps performance just to keep your obfuscation and false narratives alive
but here's to you spuddering Mr. Redspudder
SMH - can't make this shite up...!
MOO shill
MONI to release RM acquisition news
BAF MONI
hey 'reputation ruined' Redsputter - like 3 R's in a row
nice snippet - but that hysterical bad entry will soon be corrected
I'll have it served up to you - like room service - in your roach motel
but you sir - you have this atrocity to recon with the countless TOMDF SH's that followed you off the financial cliff
oh the irony of it all...
better than Remdesivir - my pearly right royal cheek arse -
talk about a bad endorsement..!
SMH - celebrity touch football - how pathetic
how many TOMDF shares was JN paid for this little fiasco...?
MOO - oh lala
hey Redsputter - lil Boiler Room Promo Boi
where's your alter ego alias "theWordman" hiding today...?
uhm - just as a reminder - there's 3.3-Bil. OS shares out - yes that's spelled "BILLION" brah...!
a $0.0001 pps increase ain't much of a change scooter pie...
its a long way home pal - like a few thousand universes away - from anything remotely considered a 'normal' pps
so don't spas out just yet sporto - or we'll have to call nurse Ratchet - yikes - nothing like the thorazine shuffle...!
SMH - can't make this stuff up
MOO gumbie
all lies...
thanks for the kind words VCF
unfortunately, AMBS has repeated itself all over again...!
not only with the notorious Astoria Queens toxic death spiral, cheap convertible financial mafia, which eviscerates all SH investment dollars
all orchestrated by non-other than Gerald Commissiong - the Stanford "Financial Engineer" CEO hack
but also the same AMBS/TOMDF Back Office Pump Boy circus actors
consisting of the same scum sucking Redspeed, JoeForkeyBolo and theWordman (who actually doubles as Redspeed)
these shills and touts will do and say "anything" to try and entice the novice and unsuspecting investor to buy into this sham
SMH - sad but true
MOO sinful
hey JoeyForkitBolo - or is it really Warpcore - wink wink...!
who in hell would believe YOU after your below Reddit post...?
what a fake, what a fraud, what a fugazi...
IMHO this says it all for folks the TOMDF Back Office Pumper Boy JFB ...
who has ulterior motives in separating you from your hard earned money:
SMH - can't make this stuff up
MOO dolts
hey Wordie - or is it really Redsputter - wink wink...!
in addition to the nose bleed, lip smacking, eye popping and hair pulling atrocious $0.0002 pps TA Chart
these TOMDF sham PR's will lube your ratchets for ya...!
TOMDF Sham Exposed in PR Chronological Order
Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
Sep 26, 2023 11:01am EDT
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
Aug 30, 2023 8:19am EDT
Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics
Mar. 28, 2023
Todos Medical Begins Trading on the OTC Pink Marketplace
Mar. 27, 2023
Todos Medical Supports Long COVID Awareness Day
Mar. 15, 2023
Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders
Mar. 13, 2023
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics
Feb. 14, 2023
Todos Medical to Present at the RHK 2022 Disruptive Growth Conference
Dec. 06, 2022
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
Nov. 29, 2022
Todos Medical to Attend World Antiviral Congress
Nov. 22, 2022
Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
Nov. 16, 2022
Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A.
Nov. 10, 2022
Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA
Oct. 14, 2022
Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics
Oct. 06, 2022
Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform
Sep. 30, 2022
Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™
Sep. 27, 2022
Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd Hemp
Sep. 22, 2022
Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for #TolloUp Campaign
Sep. 16, 2022
Todos Medical Announces Preprint of Long COVID Case Study Participant with Confirmed Microclot and Hyperactivated Platelets who Benefitted from Tollovid
Sep. 15, 2022
Todos Medical & The Alchemist’s Kitchen to Host “Long COVID: An Integrated Approach” Event Benefitting Survivor Corps
Sep. 13, 2022
Todos Medical’s 3CL Protease Inhibitor Supplement Tollovid™ Featured in Wellness Magazine
Sep. 13, 2022
Todos Medical Partner NLC Pharma Assigns IP for Tollovir™, Tollovid™, and TolloTest™ into JV 3CL Pharma
Sep. 12, 2022
Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti
Sep. 09, 2022
Todos Medical Announce Kingcarlx as Brand Ambassador for the Tollovid #TolloUp Lifestyle Campaign
Sep. 02, 2022
Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production
Aug. 31, 2022
Todos Medical Expands COVID Onsite School Sample Collection to Include MonkeyPox Testing
Aug. 29, 2022
Todos Medical Announces Saliva-Only MonkeyPox Testing at CLIA/CAP Clinical Lab Provista Diagnostics
Aug. 26, 2022
Todos Medical Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series
Aug. 25, 2022
Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women
Aug. 23, 2022
Todos Medical Announces Commercialization of Lesion and Saliva-Based MonkeyPox PCR Testing
Aug. 22, 2022
Todos Medical Announces Preprint of Data from First 100 Participants in IRB-waived Market Research Study of Supplementation with Tollovid in Long COVID
Aug. 19, 2022
Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID
Aug. 15, 2022
Todos Medical Completes Trial Design for Tollovid™ Long COVID Clinical Study in Adults
Aug. 11, 2022
Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels at CLIA/CAP Lab Provista Diagnostics
Aug. 10, 2022
Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Aug. 08, 2022
Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics
Aug. 05, 2022
Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Aug. 03, 2022
Todos Medical Announces Preprint of Acute COVID-19 Paxlovid Rebound Rescued by Tollovid
Aug. 01, 2022
Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel
Jul. 28, 2022
Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid® Treatment Followed by Tollovid™ Dietary Supplementation
Jul. 22, 2022
Todos Medical Reports Case Study #7 in Acute and Long COVID
Jul. 12, 2022
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
Jun. 30, 2022
Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID
Jun. 23, 2022
Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff
Jun. 21, 2022
Todos Medical Completes Validation of 27 Pathogen UTI PCR Panel at Its CLIA/CAP Laboratory Provista Diagnostics
Jun. 13, 2022
Todos Medical Reports Day 45 Update for Case Study #6
Jun. 10, 2022
Todos Medical Reports Day 28 Update for Case Study #5 with Erectile Dysfunction
Jun. 07, 2022
Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET
Jun. 03, 2022
Todos Medical Reports Day 26 Update For Case Study #4
Jun. 01, 2022
Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference
May 27, 2022
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient
May 06, 2022
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
May 02, 2022
Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022
Apr. 27, 2022
Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics
Apr. 21, 2022
Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study
Apr. 20, 2022
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group
Apr. 19, 2022
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label
Apr. 06, 2022
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
Apr. 04, 2022
Todos Medical Reports Case Study of Patient with Long COVID
Mar. 31, 2022
Billy Blanks® Endorses Todos Medical’s Line of Tollovid® Products
Mar. 28, 2022
Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma
Mar. 16, 2022
Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs
Mar. 08, 2022
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
Jan. 27, 2022
Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Jan. 24, 2022
Pepperdine University Hosts the 22nd Annual Celebrity Flag Football Challenge®, Presented by Todos Medical’s Tollovid®
Jan. 19, 2022
Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies
Jan. 18, 2022
Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022
Jan. 12, 2022
Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022
Jan. 10, 2022
Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista
Dec. 27, 2021
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer’s Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing
Dec. 23, 2021
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
Dec. 22, 2021
Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing
Dec. 20, 2021
Todos Medical Announces “Test & Tollovid®” Holiday Package for Atlanta Area at Provista Diagnostics
Dec. 17, 2021
Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19
Dec. 16, 2021
Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes
Dec. 13, 2021
Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST
Dec. 10, 2021
Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics
Dec. 07, 2021
CEOs Presenting at the Emerging Growth Conference on December 8; Register Now
Dec. 07, 2021
Todos Medical to Present at Upcoming Emerging Growth Conference
Dec. 06, 2021
Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
Dec. 02, 2021
Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant
Nov. 30, 2021
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma
Nov. 29, 2021
Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece
Nov. 22, 2021
Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
Nov. 19, 2021
Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe
Nov. 18, 2021
Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test
Nov. 17, 2021
Todos Medical’s Provista Laboratory to Boost Top Line Through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests
Nov. 16, 2021
Todos Medical Reports Third Quarter 2021 Business and Financial Results
Nov. 15, 2021
Todos Medical Sees Significant Ramp Up in COVID PCR Testing Volume at Its Provista CLIA/CAP Lab with New Automation in Place
Nov. 02, 2021
Todos Medical Announces 2nd Clinical Trial Site for Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Nov. 01, 2021
Todos Medical Announces Publication in Nature Neuroscience That Describes the Main Protease (3CL Protease) Causes Microvascular Brain Pathology
Oct. 25, 2021
Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection
Oct. 21, 2021
Todos Medical to Conduct Webinar Highlighting the cPass SARS-COV-2 Neutralizing Antibody Test for AMDA, The Society for Post-Acute and Long-Term Care Medicine, on October 22, 2021 at 12:00 PM EDT
Oct. 14, 2021
Todos Medical Announces Positive Data in Hospitalized and Outpatient Setting for TolloTest™, a Novel SARS-CoV-2 3CL Protease Biomarker Assay
Oct. 06, 2021
Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck
Oct. 04, 2021
Todos Medical Announces Positive Observational Trial Results for Oral Antiviral 3CL Protease (MPro) Inhibitor Tollovir®
Sep. 30, 2021
Todos Medical Receives Approval by Amazon to Sell Immune Supplements Tollovid® & Tollovid Daily™
Sep. 27, 2021
Todos Medical Reports Second Quarter 2021 Financial Results
Fri, Sep. 24, 2021
UPDATE: Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep. 24, 2021
Todos Medical Launches Tollovid Daily™ via Subscription at MyTollovid.com
Sep. 23, 2021
Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Oral Antiviral Drug Candidate Tollovir™
Sep. 20, 2021
Todos Medical Now Accepting Cryptocurrency for the Purchase of Tollovid® and Tollovid Daily™ Through Coinbase Commerce
Sep. 17, 2021
Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep. 15, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of Combination COVID, Influenza A & B, RSV & hMPV Respiratory Panel Test
Sep. 01, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants
Aug. 26, 2021
Todos Medical’s CLIA/CAP Lab Provista Enters Into Reference Lab Agreement with Meadowlands Diagnostics to Provide cPass Neutralizing Antibody Blood Testing for Quantifying and Monitoring Key COVID-19 Immunity Biomarkers
Aug. 24, 20211
Todos Medical Completes Validation of cPass Neutralizing Antibody Blood Test at Provista Diagnostics to Quantify and Monitor Key Biomarkers of COVID-19 Immunity
Aug. 23, 2021
Todos Medical CEO to Appear on Fox Business Network Varney & Company Today at 11:40am to Discuss the Company’s Launch of cPass Neutralizing Antibody Testing for Monitoring COVID-19 Immunity
Aug. 23, 2021
Update: Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug. 05, 2021
Todos Medical Receipt Notice of Allowance from USPTO for 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug. 05, 2021
Todos Medical Makes Final Payment to Close Provista Diagnostics Acquisition
Aug. 02, 2021
Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir
Jul. 28, 2021
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Daily™ Including 3CL Protease Inhibitor Claim
Jul. 22, 2021
Todos Medical to Launch EUA Authorized cPass SARS-CoV-2 Neutralizing Antibody Kit Through Agreement with Fosun Pharma
Jul. 19, 2021
Todos Medical Appoints Ilanit Halperin, CPA as Corporate Controller
Jul. 07, 2021
Todos Medical Receives FDA Certificate of Free Sale for New 5-Day Tollovid Dosing Regimen
May 04, 2021
Todos Medical Launches Phase 2 Clinical Trial of Its Antiviral 3CL Protease Inhibitor NLC-V-01 (Tollovir) in Hospitalized COVID-19 Patients
Apr. 19, 2021
Todos Medical Receives Notice of Allowance from European Patent Office for Patent Application Covering Diagnosis of Cancer Using Proprietary Artificial Intelligence TBIA Immune Profiling Platform
Apr. 08, 2021
Todos Medical Completes Automation Equipment Installation and Training for Meadowlands Diagnostics
Apr. 01, 2021
Todos Medical Enters Into Distribution Partnership with Osang Healthcare for the GeneFinder Plus™ COVID-19 Plus RealAMP Kit in the United States
Mar. 30, 2021
Todos Medical Completes Automation Equipment Installation and Training for a Laboratory Client in Brooklyn, NY
Mar. 29, 2021
Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics
Mar. 23, 2021
Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021
Mar. 12, 2021
Todos Medical Applauds Senate and House Passage of the American Recovery Act
Mar. 11, 2021
Todos Medical Announces Strategic Investment by Yozma Group Korea
Jan. 25, 2021
Todos Medical Announces $4.8 Million in Sales for December 2020, a 50% Month Over Month Increase in Sales from November 2020
Jan. 11, 2021
Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of Kentucky
Dec. 23, 2020
Aditxt Signs Distribution Agreement with Todos Medical Ltd. For AditxtScore™ for COVID-19 Immune Monitoring Service
Dec. 14, 2020
Todos Medical Announces Commercial Launch of Proprietary 3CL Protease Inhibitor Dietary Supplement Tollovid™ at The Alchemist’s Kitchen
Dec. 07, 2020
Todos Medical Announces $3.2 Million in Sales for November 2020, a 269% Increase Sequential Month over Month Sales Growth from October 2020
Dec. 02, 2020
Todos Medical Provides Strategic Outlook
Dec. 01, 2020
Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR Testing
Nov. 24, 2020
Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action
Nov. 20, 2020
Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay
Nov. 18, 2020
Todos Medical Announces Clinical Validation and National CLIA Certification for MOTO+PARA Mobile High Complexity Labs
Nov. 17, 2020
Todos Medical Announces $867,000 in Sales for October 2020
Nov. 12, 2020
Todos Medical Trademarks Tollovid for Dietary Supplement NLC-001 and Enters Into Private Label & Distribution Agreement With The Alchemists Kitchen
Oct. 29, 2020
Todos Medical Announces Instrument Validation Complete at MOTO+PARA Mobile Lab
Oct. 26, 2020
Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep Point-of-Care Covid-19 Antibody Tests
Oct. 22, 2020
Todos Medical Receives Notices of Allowance From the European Patent Office Covering Use of TBIA Cancer Platform to Detect Benign Colon Cancer
Oct. 20, 2020
Todos Medical Reports $2.0 Million in Revenue for the Third Quarter of 2020
Oct. 13, 2020
Todos Medical Enters into Exclusive COVID-19 Testing Supply Agreement with MOTO+PARA’s National Mobile CLIA Lab Partner Integrated Health
Oct. 07, 2020
Todos Medical Enters into Exclusive Branding and Distribution Agreement with Melbourne Biotech for 96 and 384 Well RT-PCR Machines in the United States
Sep. 30, 2020
Todos Medical Enters Into COVID-19 PCR Testing Implementation and Equipment Financing Partnership with AID Genomics
Sep. 25, 2020
Todos Medical Expands Existing Contract for COVID-19 PCR Testing Equipment & Supplies with Wisconsin-based Laboratory to $47.5 Million
Sep. 22, 2020
Todos Medical CEO Releases Letter to Shareholders
Sep. 18, 2020
3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma
Sep. 17, 2020
Todos Medical Expands Partnership with Care G.B. Plus for Proprietary TBIA Cancer Tests to Include Europe, Israel and Africa
Sep. 16, 2020
Todos Medical Announces Commercial Launch of Todos Branded COVID-19 qPCR Test Kits in the United States
Sep. 11, 2020
Todos Medical Announces August Sales of $1,190,000, Up 100% Compared with July
Sep. 03, 2020
Todos Medical Enters Into Partnership With Pangea for COVID-19 Testing and Contact Tracing
Sep. 02, 2020
Todos Medical Announces $23,760,000 Contract for COVID-19 PCR Testing Equipment & Supplies With Wisconsin-based Laboratory
Aug. 31, 2020
Todos Medical to Present at The LD 500 Virtual Conference
Aug. 31, 2020
Todos Medical Announces $4,500,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
Aug. 27, 2020
Todos Medical Appoints Marsha Fontanive as VP of Sales and Chris Gross as VP of Sales Operations
Aug. 25, 2020
Todos Medical Announces $1.2 Million Contract for COVID-19 PCR Testing Equipment & Supplies with Texas-based Laboratory
Aug. 24, 2020
Todos Medical Announces $6,000,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
Aug. 21, 2020
Todos Medical Announces Positive Proof-of-Concept Data for Novel 10-Minute Point-of-Care Saliva-based Test Detecting Active SARS-CoV-2 Infection
Aug. 17, 2020
Todos Medical Acquires Distribution Rights to SARS-CoV-2 Rapid Point-of-Care Antigen Test and Rapid Point-of-Care PCR Test
Aug. 14, 2020
Todos Medical Announces July Sales of COVID-19 Tests
Aug. 07, 2020
Todos Medical Announces Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
Aug. 06, 2020
Todos Medical Appoints Dr. Jorge Leon as Consulting Chief Medical and Scientific Officer of Infectious Disease and Oncology
Aug. 04, 2020
Pathnova Laboratories (PATHNOVA) Enters into Partnership to Commercialize Todos Medicals COVID-19 and Breast Cancer Tests in Singapore
Aug. 03, 2020
Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus
Jul. 28, 2020
Todos Medical Announces SARS-nCoV-19 Testing Kit Contract with NJ-Based Best Supply Clinical Laboratory
Jul. 27, 2020
Todos Medical Expands Management Team and Advisory Board
Jul. 20, 2020
Todos Medical Announces ANVISA Authorization in Brazil for 3D Med qPCR Kits and ANDis Extraction S
Jul. 16, 2020
Todos Medical Releases Letter to Shareholders
Feb 07, 2020 9:15am EST
Todos Medical Enters into Exclusive Option Agreement to Acquire Provista Diagnostics and Announces Management Changes
Jan 09, 2020 8:00am EST
Todos To Present At Upcoming 12th Annual LD Micro Main Event
Dec 06, 2019 7:29am EST
Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET
Nov 14, 2019 11:02am EST
Todos Medical to Present at Dawson James Small Cap Growth Conference
Oct 24, 2019 9:25am EDT
Todos Medical and Orot+ Announce First Patient Enrolled in Pre-Commercial Launch Preparations of TM-B1 and TM-B2 Breast Cancer Blood Screening Tests in Europe
Sep 24, 2019 9:14am EDT
Todos Medical Signs Binding Term Sheet with HWH World for Network Marketing of Blood Tests for the Early Detection of Breast Cancer
Sep 13, 2019 7:30am EDT
Todos Medical Enters into MOU to Expand Existing Early Detection Breast Cancer Blood Test Distribution Partnership with Orot+ into Japan
Sep 03, 2019 1:29pm EDT
Todos Medical Appoints Dr. Jorge Leon as Medical Advisor
Aug 06, 2019 7:00am EDT
Todos Medical Announces Positive Alzheimer's Biomarker Clinical Data from LymPro vs. Amyloid PET Interim Analysis
Jul 15, 2019 7:00am EDT
Todos Medical CEO Presented Corporate Update And Roadmap at The LD Micro Conference
Jun 17, 2019 8:30am EDT
Todos Medical Announces Positive Clinical Trial Data for Breast Cancer Blood Test TM-B1 in Dense Breasts
Jun 03, 2019 8:00am EDT
Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data
May 28, 2019 8:57am EDT
Todos Medical Receives Approval from Israeli Ministry of Health (AMAR) to Market and Sell its Breast Cancer Screens in Israel
May 23, 2019 8:00am EDT
Todos Medical Enters Exclusive Distribution Agreement with Care G.B. Plus, Ltd. for its Breast Cancer Screening Tests in Israel
May 21, 2019 8:00am EDT
Todos Medical Announces Voting Results from 2019 Annual Shareholder Meeting
May 03, 2019 8:52am EDT
Todos Medical Receives Notice of Allowance from the USPTO Covering the Early Diagnosis of Lung Cancer Using the Todos Biochemical Infrared Analysis (TBIA)
May 01, 2019 8:00am EDT
Todos Medical Enters Into Definitive Agreement With Orot+ for Exclusive Distribution Rights of its Breast Cancer Screening Tests in 2 European Countries
Apr 15, 2019 8:00am EDT
Todos and Amarantus Announce Completion of LymPro PET 1 Study by Leipzig University for Alzheimer’s Blood Diagnostic LymPro Test 2.0
Apr 08, 2019 7:30am EDT
Todos Medical to Present at Two Upcoming Investor Conferences
Mar 28, 2019 8:00am EDT
Todos Medical Appoints Dr. Colin Bier to Its Board of Directors
Mar 27, 2019 8:00am EDT
Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience
Feb 28, 2019 9:30am EST
Todos Medical Presents Encouraging Scientific Abstract at the San Antonio Breast Cancer Symposium (SABCS)
Dec 06, 2018 4:00pm EST
Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0
Dec 03, 2018 8:30am EST
Todos Medical to Present Scientific Abstract at the Upcoming San Antonio Breast Cancer Symposium (SABCS)
Nov 29, 2018 8:30am EST
Todos Medical, Ltd. Announces Additional Patent Issuance Covering the Use of IR Spectrum of Blood Plasma For Indicating the Presence of Breast Cancer
Oct 17, 2018 8:30am EDT
Todos Medical, Ltd. Signs Non-Binding Memorandum of Understanding with Orot+ for Distribution Rights of its Breast Cancer Screening Tests in Romania and Austria
Sep 13, 2018 8:30am EDT
Todos Medical, Ltd. Appoints Herman Weiss, MD MBA as New Chief Executive Officer
Jul 31, 2018 4:03pm EDT
Todos Medical reports on results of clinical trials for its blood test for breast cancer screening (TM - B1) conducted at Kaplan Hospital in Rehovot, Israel
Mar 22, 2018 8:00am EDT
Todos Medical initiates clinical trial of its blood test for breast cancer in Kaplan Hospital, Rehovot, Israel for subjects undergoing breast cancer screening
Mar 05, 2018 8:00am EST
U.S. Patent and Trademark Office has granted to Todos Medical two additional patents
Feb 12, 2018 8:00am EST
Mr. David Ben Naim, CPA, MBA Joins Todos Medical as Chief Financial Officer
Feb 06, 2018 8:00am EST
Todos Medical Appoints Dr. Meir Silver as Vice President of Clinical Research and Regulatory Affairs
Aug 29, 2017 8:30am EDT